A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

NCT02479178 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma
Cholangiocarcinoma
Cervical Cancer
Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: BIND-014 (docetaxel nanoparticles for injectable suspension)

Sponsor

BIND Therapeutics